Press releases from 2024 to 2016
Press releases
2024
- 28/08/2024 - AMOEBA prepares for the commercial launch of the AXPERA Product Line in the USA with approval expected by 2025
- 02/07/2024 - A new legal structure to maximise commercial activities
- 11/06/2024 - Commercial presentation available
- 10/06/2024 - Confirmation of the development potential of Amoeba in cosmetics
- 23/05/2024 - Ordinary and Extraordinary General Meeting of 27 June 2024
- 02/05/2024 - Amoéba's Board of Directors renewed to support the company's new strategic ambitions
- 29/04/2024 - AMOEBA annouces availability of Universal Registration Document 2023
- 28/03/2024 - AMOEBA: full year earnings- a year of transition in preparation for the launch of its products
- 15/02/2024 - Additional information and areas for growth
- 05/02/2024 - Corporate governance change reminder and review of the company's growth strategy
2023
- 15/12/2023 - AMOEBA: Commercial strategy and governance further strengthened and industrial project deferred
- 23/11/2023 - AMOEBA : A year of field trials that confirms AXPERA's strategic positioning
- 27/10/2023 - AMOEBA : 2023 Interim Financial Report
- 18/10/2023 - AMOEBA announces the publication of a scientific paper concerning the efficacy of its biocontrol products to fight tomato late blight and powdery mildews of tomato
- 16/10/2023 - AMOEBA announces promising results for the use of amoeba lysate in cosmetics, and has filed a patent application for this invention.
- 12/10/2023 - AMOEBA announces the start of work on the USIBIAM industrial project
- 05/10/2023 - AMOEBA announces its half-year results for 2023
- 22/09/2023 - AMOEBA: final stages of development of 100% biocontrol plant in Cavaillon
- 17/07/2023 - AMOEBA confirms that the regulatory timetable for Europe's biocontrol application is on track
- 05/06/2023 - AMOEBA introduces its AXPERA brand for the biocontrol application
- 20/04/2023 - AMOEBA announces the initiation of coverage by Portzamparc
- 19/04/2023 - ORDINARY AND EXTRAORDINARY GENERAL MEETING TO BE HELD ON 25 MAY 2023 - MODALITIES THROUGH WHICH THE PREPARATORY DOCUMENTS WILL BE MADE AVAILABLE
- 18/04/2023 - AMOÉBA announces the availability of the 2022 Universal Registration Document including the Annual Financial Report
- 31/03/2023 - Amoéba announces its collaboration with Nissan Chemical Corporation for the biocontrol application
- 30/03/2023 - Amoéba : 2022 annual results – An exceptional year which confirms Amoéba’s potential
- 29/03/2023 - Amoéba obtains €5.9 million in funding from BPI France as part of France 2030 program
- 13/03/2023 - AMOEBA announces initiation report from the analyst Edison Group
- 16/02/2023 - Amoéba submits the AMOEBA submits the building permit application for its 100% biocontrol manufacturing unit in the south of France Lyon (France), February 16, 2023 - 5:45 p.m. - AMOÉBA (FR0011051598 - ALMIB), an industrial biotech in pre-commercialization* that is specialized in the treatment of microbiological risk, developing a biocontrol agent for the treatment of plants in agriculture and a biological biocide for the treatment of industrial water, announces that it has applied for building permit for its new production site dedicated to biocontrol application
- 15/02/2023 - AMOEBA signs a new €9 million simple bond financing agreement with Nice & Green
- 27/01/2023 - Cancellation of the issue of the 8th optional tranche of OCAs and signature of a support contract with Redbridge Debt and Treasury Advisory
2022
- 20/12/22 - US EPA approves Amoeba's biocide for use in closed cooling systems
- 14/12/22 - Amoéba announces the issuance of the 7th tranche of 40 bonds convertible into shares
- 03/11/22 - US EPA approves Amoeba's biocontrol solution for agricultural use
- 20/10/22 - Amoéba: a record year for the number and performance of field trials
- 19/10/22 - Amoeba withdraws its biocide file in Canada to focus its resources on strategic priorities
- 18/10/22 - Publication of a scientific article concerning the efficacy of Amoéba's biocontrol products to fight potato late blight
- 12/10/22 - US EPA approves tolerance exemption for the biocontrol active substance on foodstuffs
- 03/10/22 - 2022 Interim Financial Report
- 29/09/22 - Amoéba announces its half-year results for 2022
- 29/09/22 - US EPA about to approve Amoéba’s biocontrol solution for use in agriculture
- 15/09/22 - Amoéba announces the issuance of the sixth tranche of 60 bonds convertible into shares
- 10/08/22 - US EPA about to approve Amoeba's biocide for use in closed cooling systems
- 07/07/22 - Deferral of the 6th tranche of OCA's
- 13/06/22 - Amoéba announces the issuance of the 5th tranche of 60 bonds convertible into shares
- 30/05/22 - Amoeba: US regulatory calendar update
- 06/05/22 - General Assembly of 24 may 2022 - Modalities through which preparatory documents are made available
- 03/05/22 - Malta recommends the non-approval of the biocide active substance for the european territory
- 25/04/22 - Austria recommends the approval of the biocontrol active substance for the european territory
- 13/04/22 - Availability of the 2021 Universal Registration Document
- 05/04/22 - Deferral of the 5th tranche of OCA's
- 31/03/22 - Amoéba 2021 results
- 25/03/22 - Update of the European regulatory application calendar
- 07/03/22 - Amoéba announces the issuance of the 4th tranche of bonds convertible into shares
- 25/01/22 - Amoéba stenghens its Board of directors by co-opting a new director
- 07/01/22 - Deferral of the 4th tranche of OCA's
2021
- 14/12/21 - Update of the regulatory application calendar
- 15/11/21 - The Maltese authority announces to Amoeba a conclusion of the biocidal active substance dossier evaluation at the end of March 2022.
- 20/10/21 - Publication of a new paper in the scientific journal "Pathogens"
- 07/10/21 - Amoéba announces the issuance of the third tranche of 60 bonds convertible into shares
- 04/10/21 - Availability of the 2021 Interim Financial report
- 30/09/21 - Amoéba announces its half year results 2021
- 24/08/21 - A second cereal trial campaign confirms the potential of the biocontrol product of Amoéba
- 29/07/21 - Promising results of the Biocontrol-Grapevine application
- 06/07/21 - Amoéba announces the issuance of the second tranche of 60 bonds convertible into shares
- 05/07/21 - Amoéba announces a postponement of the conclusion of the evaluation by Malta of the biocide active substance dossier
- 24/06/21 - Evolution of the composition of the board of directors of Amoéba
- 02/06/21 - Availability of the preparatory documents to the General Meeting of June 24,2021
- 27/05/21 - Amoéba announces the second convocation of its General Meeting
- 10/05/21 - Availability of the preparatory documents for the General meeting of 27 may 2021
- 12/04/21 - Availability of the 2020 Universal Registration Document
- 07/04/21 - Amoéba announces the issuance of the 1st tranche of 60 bonds convertible into shares
- 06/04/21 - Amoéba submits its biocide application in the USA
- 06/04/21 - Amoéba launches a massive new field trials campaign for 2021
- 26/03/21 - Amoéba announces the 2020 financial year results
- 04/03/21 - Amoéba announces the issuance of the 12° tranche of bonds convertible into shares
- 04/02/21 - Amoéba announces the issuance of the 11° tranche of bonds convertible into shares
- 06/01/21 - Amoéba announces the issuance of the 10° tranche of bonds convertible into shares
2020
- 21/12/20 - Amoéba renews a financing line of up to €23M with Nice & Green to support its development
- 18/12/20 - Amoéba signs a non-exclusive development and marketing agreement in Switzerland with STÄHLER for its vine biocontrol product
- 17/12/20 - Amoéba announces the appointment of Pierre MORGON as censeur on the Board of Directors
- 09/12/20 - Amoéba signs an exclusive development and marketing agreement in France with PHILAGRO for its grapevine biocontrol product
- 07/12/20 - Amoéba extends to the USA the testing of its biocontrol products with GOWAN COMPANY
- 04/12/20 - Amoéba announces the issuance of the 9th tranche of bonds convertible into shares
- 16/11/20 - Amoéba publishes a new scientific paper in the journal microorganisms
- 06/11/20 - Amoéba announces the issuance of the 8th tranche of bonds convertible into shares
- 06/10/20 - Amoéba announces the issuance of the 7th tranche of bonds convertible into shares
- 01/10/20 - Amoéba files the application for the authorization of its biocontrol solution in the U.S.A
- 25/09/20 - 2020 Interim Financial Report
- 24/09/20 - Amoéba announces half-year results in line with those of 2019 and continues to develop its biocide and biocontrol applications
- 10/09/20 - Transfer of Amoéba's shares to the Euronext Growth Paris market
- 04/09/20 - Amoéba announces the issuance of the 6th tranche of bonds convertible into shares
- 11/08/20 - Amoéba publishes a first scientific article concerning its biocontrol application to fight grapevine downy mildew
- 06/08/20 - Amoéba announces the issance of the 5th tranche of bonds convertible into shares
- 27/07/20 - Efficacy of the biocontrol solution against grapevine downy mildew confirmed through the second european field trials campaign
- 22/07/20 - Field tests confirm the efficacy of Amoeba's biocontrol solution on several major wheat diseases
- 06/07/20 - Amoéba announces the issuance of the 4th tranche of bonds convertible into shares
- 24/06/20 - Approval by the General Meeting of the transfer of Amoéba's shares to Euronext growth
- 10/06/20 - Availability of the preparatory documents to the General Meeting of June 24, 2020
- 05/06/20 - Amoéba announces the issuance of the third tranche of bonds convertible into shares
- 05/06/20 - Amoéba publishes a new scientific article in the Pathogens journal
- 29/05/20 - Amoéba has filed the application for approval of its biocontrol solution in Europe
- 28/05/20 - Amoéba announces the second convening of its shareholders' meeting
- 22/05/20 - Amoéba publishes a new scientific article in the Microorganisms journal
- 13/05/20 - Availability of the preparatory documents to the General Meeting of 28 May 2020
- 04/05/20 - Amoéba announces the issuance of the second tranche of bonds convertible into shares
- 30/04/20 - Availability of the 2019 Universal Registration Document
- 29/04/20 - With 8 research partnerships in biocontrol, Amoéba confirms a new development phase
- 22/04/20 - Amoéba signs a Material Transfer Agreement with BAYER for its biocontrol solutions
- 16/04/20 - Syngenta and Amoéba launch a targeted research phase in biocontrol products
- 14/04/20 - Amoéba biocontrol solutions tested by EVERGREEN GARDEN CARE
- 06/04/20 - Amoéba announces the issuance of the first tranche of 26 bonds convertible into shares
- 02/04/20 - Biocontrol development partnership in France and Europe between Amoéba, PHILAGRO France and NICHINO Europe
- 31/03/20 - Signature of an amendment to the financing contract with the EIB and project to issue warrants
- 31/03/20 - BASF evaluates Amoéba's biocontrol products
- 30/03/20 - Amoéba biocontrol products selected by Certis Europe for evaluation on european vineyards
- 27/03/20 - Project to transfer Amoéba's shares to Euronext Growth Paris
- 27/03/20 - Amoéba announces 2019 results in line with its development
- 25/03/20 - STÄHLER SUISSE SA evaluates Amoeba biocontrol products on grapes and potatoes
- 18/03/20 - DE SANGOSSE Group is evaluating Amoeba's biocontrol products
- 17/03/20 - General Shareholders' meeting of March 13, 2020
- 09/03/20 - Amoéba announces the signature of an amendment to the contract for the issue of bonds convertible into shares
- 24/02/20 - Availability of the preparatory documents to the general meeting of march 13 2020
- 07/02/20 - Amoéba announces the publication of an article which reconfirms the direct effect of predation and elimination of legionella by the amoeba Willaertia magna C2c Maky
- 30/01/20 - Amoéba announces the second convening at the shareholders'meeting
- 17/01/20 - Amoéba announces the filing of the Universal Registration Document and the availability of the prospectus approved by the AMF as part of its new financing through bonds convertible into shares
- 15/01/20 - Availability of the preparatory documents to the general meeting of january 30, 2020
2019
- 2019/12 - Amoéba announces the signature of a new contract for the issuance of bonds convertible into shares
- 2019/12 - Amoéba announces the issuance of the twelfth tranche of 26 bonds convertible into shares
- 2019/12 - Amoéba publishes in Scientific Reports the complete genomic analysis of Willaertia magna C2c Maky
- 2019/11 - Amoeba annonces the issuance of the eleventh tranche of 26 bonds convertible into shares
- 2019/10 - Amoeba announces the issuance of the tenth tranche of 26 bonds convertible into shares
- 2019/09 - 2019 Interim financial report
- 2019/09 - Amoeba announces half year results in line with 2018 and continues to develop its biocide and biocontrol applications
- 2019/08 - Amoéba informs about the postponement of the publication date of the half yearly accounts
- 2019/08 - Amoéba announces the issuance of the 9th tranche of 26 bonds convertible into shares
- 2019/08 - Amoéba informs that the EPA cannot grant the registrations for the use of its active substance in cooling towers
- 2019/08 - Amoéba announces the issuance of the 8th tranche of 26 bonds convertible into shares
- 2019/08 - Amoéba announces the submission in Europe of a new application for approval of its biocidal active substance
- 2019/07 - Amoéba announces results confirming the field efficacy of its active substance against grapevine downy mildew
- 2019/06 - Amoéba announces the issuance of the 7th tranche of 26 bonds convertible into shares
- 2019/07 - Amoéba announces the possible use of its substance for the treatment of one of the pathogens of field crops
- 2019/06 - Descriptif du programme de rachat d'actions autorisé par l'assemblée générale du 20 juin 2019
- 2019/06 - Changes in the composition of Amoeba's Board of Directors
- 2019/05 - Amoéba announces the issuance of the 6th tranche of 26 bonds convertible into shares
- 2019/05 - Amoéba announces that the decision of the US EPA is expected at the end of August 2019
- 2019/05 - Availability of the preparatory documents to the general meeting of june 20, 2019
- 2019/05 - Amoéba announces the issuance of the fifth tranche of 26 bonds convertible into shares
- 2019/04 - Amoéba announces the availability of its 2018 Registration Document
- 2019/04 - Amoéba announces the issuance of the fourth tranche of 26 bonds convertible into shares
- 2019/03 - Amoéba announces that the dossier for its biocidal active substance approval is still under scientific review by the US EPA
- 2019/03 - 2018 annual results in line with the company's repositioning
- 2019/03 - Amoéba announces the issuance of the third tranche of 26 bonds convertible into shares
- 2019/03 - Amoéba announces that its active substance has an eliciting action on the vine and a direct action on the germination of grape downy mildew
- 2019/02 - Amoéba announces that Malta has agreed to be the reviewer of the new application for approval of its active substance for biocidal application in Europe
- 2019/02 - Amoéba announces the issuance of the second tranche of 26 bonds convertible into shares
- 2019/02 - Amoéba announces that Austria has accepted to be the Rapporteur Member state to start the evaluation of its biocontrol active substance in Europe in the first quarter of 2020 with a view to a potential commercialisation in 2025
- 2019/02 - Amoéba announces a major scientific advance of the formulation of its amoeba Willaertia magna C2c Maky intended for plant protection
- 2019/02 - Amoéba informs on the status of the applications for registration of its biocidal product in the United States and Canada
- 2019/01 - Amoéba announces the issuance of 26 bonds convertible into shares as part of its bond financing
2018
- 2018/12 - Availability of preparatory documents for the shareholders' general meeting on january 14th 2019
- 2018/12 - Amoéba announces the approval by the AMF of the operation note relating to the OCAPI financing program and informs about the development status of the various applications and the next regulatory deadlines
- 2018/12 - Amoéba announces the signature of an amendment to the financing contract (OCAPI) and a subordination agreement
- 2018/11 - Amoéba announces the result of the European vote on the non-approval and informs on the medium term prospect of submitting an updated dossier.
- 2018/11 - Results of a safety and efficacy study assessing the fate of Legionella Pneumophila in Willaertia magna C2c Maky.
- 2018/11 - 2018 interim financial report
- 2018/09 - The Board of Directors nominates Bernard AMBOLET as new independant Director
- 2018/07 - 2018 half year results impacted by the company repositioning
- 2018/07 - Amoéba announces that it has reached the last phase of the assessment for its regulatory dossier in the united States
- 2018/07 - Amoéba announces the establishment of a € 6 million bond financing line
- 2018/07 - Amoéba and Earthwise announce positive efficacy results for the first field test in the U.S.A.
- 2018/06 - Availability of preparatory documents for the annual General Meeting on 21st June 2018
- 2018/06 - Amoéba informs of the release of the Biocidal Products Committee opinion
- 2018/06 - Amoéba announces its plan of restructuring
- 2018/05 - Amoéba announces efficacy results of more than 90% for Willaertia magna C2c Maky on vine mildew
- 2018/04 - Amoéba informs of the adoption by the Biocidal Product Committee of the non-approval o the active substance
- 2018/04 - Amoéba confirms the European regulatory stages
- 2018/03 - 2017 full-year results in line with development plan
- 2018/01 - Half-year review of the liquidity contract on 31st december 2017
2017
- 2017/11 - AMOEBA et CONIDIA validate the effect of Willaertia Magna as a biocontrol agent for the prevention of plant diseases
- 2017/11 - AMOEBA signs a Letter of Intent with H2O FACILITIES
- 2017/10 - European Investment Bank (EIB) provides EUR 20m credit line to Amoéba to revolutionise water treatment
- 2017/09 - 2017 Interim Financial Report
- 2017/09 - 2017 half-year results in line with the Group's expectations
- 2017/09 - AMOEBA signs a distribution agreement with DREWO
- 2017/09 - AMOEBA communicates about European Working Group held on its regulatory dossier
- 2017/07 - AMOEBA signs a Letter of Intent with MOMAR
- 2017/07 - Half-year review of the liquidity contract on 30th June 2017
- 2017/06 - AMOEBA and VISCUS BIOLOGICS announe a joint program for the treatment of multi-resistant bacteria for human wound care
- 2017/06 - Availability of preparatory documents for the annual General Meeting on 22nd June 2017
- 2017/05 - AMOEBA signs first distribution agreement in the USA with EARTHWISE
- 2017/05 - NOVOCHEM signs a distribution agreement for the Benelux
- 2017/05 - AMOEBA signs a Letter of Intent for the distribution of BIOMEBA in Romania
- 2017/04 - AMOEBA announces the publication of its registration document for the 2016 period
- 2017/03 - 2016 full-year results in line with development plan
- 2017/03 - AMOEBA announces receipt of the evaluation report from the French competent authority, ANSES
- 2017/03 - Arnaud MERIENNE appointed General Manager of AMOEBA
- 2017/02 - AMOEBA to start R&D tests in the USA
- 2017/02 - AMOEBA signs a Letter of Intent with KROFF CHEMICAL COMPANY
- 2017/01 - AMOEBA extends the protection of its technology in France and China
- 2017/01 - AMOEBA signs a Letter of Intent with GARRATT-CALLAHAN
- 2017/01 - AMOEBA extends its commercial network in Italy : signature of a LOI with NCR Biochemical
- 2017/01 - Half-year review of the liquidity contract on 31st december 2016
2016
- 2016/12 - AMOEBA announces update of the regulatory calendar in the United States of America
- 2016/12 - AMOEBA extends its commercial cover with the signature of a new letter of intent with OXIDINE to distribute BIOMEBA in Spain
- 2016/12 - AMOEBA confirms the submission of its comments to the French regulatory authority
- 2016/11 - AMOEBA announces receipt of the first draft of the regulatory evaluation report
- 2016/10 - AMOEBA inaugurates its first industrial site in Lyon - Chassieu
- 2016/09 - AMOEBA obtains Marketing Authorisation for R&D purposes for 10 industrial sites in Spain
- 2016/09 - AMOEBA granted Marketing Authorisation for R&D for 10 industrial sites in Germany
- 2016/09 - Interim financial report 2016
- 2016/09 - A Letter of Intent signed with AQUA-SERV in the United States for the distribution of BIOMEBA in three New States